Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01946204 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

Study acronym: SPARTAN
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 130 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. New version filed on ClinicalTrials.gov
  2. Study sites revised (379)v129
  3. 20 versions Re-verified since Jan 8, 2025, no change to tracked fieldsv109-v128
  4. Primary completion date: May 2017 to May 19, 2017
    • Study completion date: Dec 2027 to Dec 31, 2027
    • Start date: Oct 2013 to Oct 14, 2013
    • Study sites revised (379)
    v108
  5. Primary completion date: May 19, 2017 to May 2017
    • Study completion date: Dec 31, 2025 to Dec 2027
    • Start date: Oct 14, 2013 to Oct 2013
    v107
Show 26 earlier versionsHide 26 earlier versions
  1. 4 versions Re-verified since Jun 18, 2024, no change to tracked fieldsv103-v106
  2. Primary completion date: May 2017 to May 19, 2017
    • Study completion date: Dec 2025 to Dec 31, 2025
    • Start date: Oct 2013 to Oct 14, 2013
    v102
  3. 2 versions Re-verified since Mar 26, 2024, no change to tracked fieldsv100-v101
  4. Primary completion date: May 19, 2017 to May 2017
    • Study completion date: Dec 31, 2026 to Dec 2025
    • Start date: Oct 14, 2013 to Oct 2013
    v99
  5. Primary completion date: May 2017 to May 19, 2017
    • Study completion date: Dec 2026 to Dec 31, 2026
    • Start date: Oct 2013 to Oct 14, 2013
    v98
  6. Re-verified, no change to tracked fieldsv97
  7. Primary completion date: May 19, 2017 to May 2017
    • Study completion date: Dec 31, 2024 to Dec 2026
    • Start date: Oct 14, 2013 to Oct 2013
    v96
  8. 2 versions Re-verified since Oct 10, 2023, no change to tracked fieldsv94-v95
  9. Study sites: 381 to 379
    • Study completion date: Nov 8, 2023 to Dec 31, 2024
    v93
  10. 6 versions Re-verified since Mar 14, 2023, no change to tracked fieldsv87-v92
  11. Primary completion date: May 2017 to May 19, 2017
    • Study completion date: Oct 2023 to Nov 8, 2023
    • Start date: Oct 2013 to Oct 14, 2013
    v86
  12. Primary completion date: May 19, 2017 to May 2017
    • Study completion date: Nov 29, 2022 to Oct 2023
    • Start date: Oct 14, 2013 to Oct 2013
    v85
  13. 4 versions Re-verified since Aug 2, 2022, no change to tracked fieldsv81-v84
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
Trial Details
NCT Number NCT01946204
Lead Sponsor Aragon Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Prostatic Neoplasms
Related terms Prostatic Neoplasms
Enrollment 1,207 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov